ctDNA as a Response Biomarker in Solid-Tumor Oncology: Toward Routine Use in Drug-Development

Time: 3:05 pm
day: Day One


  • Review the role of ctDNA as a biomarker of therapeutic response – challenges and opportunities
  • Highlight key decision points where ctDNA is uniquely positioned to add value in drug development
  • Evaluate scenarios to showcase how the routine use of ctDNA enables stronger and faster decisions by predicting response to therapy in solid tumors